


# REAL-LIFE RESULTS ON THE USE OF TRASTUZUMAB EMTANSINE IN HER2-POSITIVE METASTATIC BREAST CANCER

Torralba-Fernández L, Labrador-Andújar N, Toledo-Davia MA, Jiménez-Méndez C, Prieto-Galindo R, Rubio-Salvador AR, Domínguez-Barahona A, Moya-Gómez P. Pharmacy. Hospital Universitario de Toledo, Spain

## BACKGROUND

Trastuzumab emtansine (T-DM1) as a single agent is approved for patients with HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with a taxane and trastuzumab.



## OBJECTIVE

To estimate the **Overall Survival (OS)** and the **Progression-Free Survival (PFS)** in patients with HER2-positive MBC treated with T-DM1. The results will be compared with those obtained with the pivotal trials.

## METHODS

- **Retrospective study**
- **Inclusion criteria:** All patients receiving T-DM1 for the treatment of HER2-positive MBC between 2016 and 2022 in a tertiary hospital.

### Variables:

- Sex, age
- ECOG stage
- Treatment duration
- Reason for discontinuation
- % Dead patients at the end of the study

### Sources:


- Electronical clinical record
- Oncohaematological prescription program
- SPSS® v.22.0



## RESULTS

- 30 patients (100% women)
- **Age** (median): 58 (48-66) years
- **ECOG 0-1** (66,7%; N=20)
- **ECOG 2** (33,3%; N=10)
- **Number of cycles** (median): 8 (3-16)
- **Treatment duration** (median): 6 (3-12) months

### Reasons for treatment discontinuation:



- **Progression:** 53,3% (N=16)
- **Death:** 10% (N=3)
- **Toxicity:** 6,7% (N=2)

At the end of the study, the 30% of patients (N=9) continued with the treatment and the 48,3% (N=14) had died

|                   | Our study                                 | TDM4450g/<br>BO21976        | TDM4370g/<br>BO21977<br>(EMILIA) |
|-------------------|---|-----------------------------|----------------------------------|
| <b>Median OS</b>  | <b>16,80</b> months<br>(95%CI 7,64-25,96) | <i>it was not estimated</i> | <b>30,9</b> months               |
| <b>Median PFS</b> | <b>10,27</b> months<br>(95%CI 5,34-15,35) | <b>14,2</b> months          | <b>9,6</b> months                |

## CONCLUSIONS

The **median PFS** in patients with HER2-positive MBC treated with T-DM1 reported in our study was **similar** than the pivotal trials. However, the **median OS** was **substantially lower** than the study TDM4450g. This difference could be mainly due to the **sample size**. Moreover, patients included in the previous study had a **better functional status** (100% ECOG 0-1) than our patients at the start of the treatment.

